T
002393
vs
S
Shanghai Composite
Over the past 12 months, Tianjin Lisheng Pharmaceutical Co Ltd has significantly outperformed Shanghai Composite, delivering a return of +47% compared to the Shanghai Composite's +26% growth.
Stocks Performance
002393 vs Shanghai Composite
Performance Gap
002393 vs Shanghai Composite
Performance By Year
002393 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tianjin Lisheng Pharmaceutical Co Ltd
Glance View
Tianjin Lisheng Pharmaceutical Co., Ltd. engages in production and sales of chemical medicine tablets, hard capsules, pills, lyophilized powder injections, water injections, and active pharmaceutical ingredient (API). The company is headquartered in Tianjin, Tianjin and currently employs 1,477 full-time employees. The company went IPO on 2010-04-23. The firm's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. The company distributes its products mainly within domestic markets.
